Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Valencia
Clinical trial register · Spain

Clinical Trials in Valencia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 188 Madrid 183 Seville 71 Málaga 66 Valencia 60
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Valencia61 AstraZeneca60 Novartis Pharmaceuticals42 Hoffmann-La Roche41 AbbVie39 Clear sponsor filter
Site location
Barcelona188 Madrid183 Seville71 Málaga66 Valencia60
All 103 locations
Target enrolment
to

Trials with a site in Valencia

60 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
AstraZeneca
Phase 3
2,800
Badajoz, Barcelona, Córdoba, Girona, Madrid, Majadahonda, Talavera de la Reina, Valencia
2026-09-01
Recruiting
AstraZeneca
Phase 3
1,072
Barcelona, Castellon, Granada, Las Palmas de Gran Canaria, Madrid, Valencia, Vigo
2026-08-31
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Barcelona, Jaén, Madrid, Murcia, Salamanca, Sanlúcar de Barrameda (Cádiz), Seville, Valencia
2026-08-24
Recruiting
AstraZeneca
Phase 3
750
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia
2026-06-26
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia
2026-06-11
Active, closed
AstraZeneca
Phase 2
326
Barcelona, Jaén, L'Hospitalet de Llobregat, Majadahonda, Málaga, Pamplona, Salamanca, Valencia
2026-06-11
Recruiting
AstraZeneca
Phase 3
245
Barcelona, Córdoba, Galdakao, Madrid, Sabadell, Santander, Seville, Valencia
2026-04-13
Recruiting
AstraZeneca
Phase 3
508
Barcelona, Madrid, Pamplona, Salamanca, Santander, Valencia
2026-02-23
Recruiting
AstraZeneca
Phase 2
124
Barcelona, Jerez de la Frontera, Valencia
2026-02-10
Recruiting
AstraZeneca
Phase 3
2,130
Barcelona, Madrid, Pamplona, Santander, Santiago de Compostela, Valencia
2026-02-03
Recruiting
AstraZeneca
Phase 2
320
Barcelona, Málaga, Sabadell, Santiago de Compostela, Valencia
2025-12-15
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Valencia
2025-11-24
Recruiting
AstraZeneca
Phase 1/2
83
Badalona(Barcelona), Barcelona, Salamanca, Santander, Valencia
2025-11-12
Recruiting
AstraZeneca
Phase 2
435
Barcelona, Benalmádena, Madrid, Mérida, Patraix, Valencia
2025-11-06
Recruiting
AstraZeneca
Phase 1
72
Barcelona, Madrid, Pamplona, Salamanca, Valencia
2025-11-03
Recruiting
AstraZeneca
Phase 3
100
A Coruña, Barcelona, Granada, Madrid, Seville, Valencia
2025-10-30
Recruiting
AstraZeneca
Phase 1/2
283
Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Valencia
2025-10-01
Recruiting
AstraZeneca
Phase 2
278
A Coruña, Madrid, Manresa, Málaga, Santander, Valencia
2025-08-07
Recruiting
AstraZeneca
Phase 2
100
Barcelona, Elche, Madrid, Málaga, Ourense, Oviedo, Santander, Valencia
2025-07-17
Recruiting
AstraZeneca
Phase 3
600
A Coruña, Córdoba, Donostia / San Sebastian, El Palmar, L'Hospitalet de Llobregat, Madrid, Palma de Mallorca, Valencia
2025-03-27
Recruiting
AstraZeneca
Phase 2
80
Barcelona, Madrid, Málaga, Pamplona, Santander, Valencia
2025-03-12
Recruiting
AstraZeneca
Phase 3
840
Badalona, Barcelona, Madrid, Ourense, Santander, Seville, Valencia
2025-03-01
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Barcelona, Madrid, Palma de Mallorca, Santiago de Compostela, Valencia
2025-01-30
Recruiting
AstraZeneca
Phase 3
582
A Coruña, Barcelona, Granada, Madrid, Majadahonda, Valencia
2024-04-29
Recruiting
AstraZeneca
Phase 3
3,850
A Coruña, Barcelona, Lugo, Madrid, Majadahonda, Seville, Valencia
2024-04-12
Recruiting
AstraZeneca
Phase 3
100
Esplugues de Llobregat, Madrid, Málaga, Santiago de Compostela, Valencia
2024-03-14
Active, closed
AstraZeneca
Phase 2
142
Barakaldo, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia, Zaragoza
2024-02-22
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Barcelona, Madrid, Salamanca, Valencia
2023-12-29
Recruiting
AstraZeneca
Phase 3
1,145
Badalona, Barcelona, Jaén, Madrid, Valencia
2023-12-14
Recruiting
AstraZeneca
Phase 1/2
564
Barcelona, Pamplona, Valencia
2023-12-05
Active, closed
AstraZeneca
Phase 3
1,898
Barcelona, Córdoba, L'Hospitalet de Llobregat, Lugo, Madrid, Sabadell, Valencia
2023-11-21
Active, closed
AstraZeneca
Phase 3
314
A Coruña, Barcelona, Madrid, Málaga, Valencia
2023-11-08
Active, closed
AstraZeneca
Phase 3
1,835
Girona, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Seville, Valencia
2023-11-07
Recruiting
AstraZeneca
Phase 3
800
A Coruña, Barcelona, Córdoba, Girona, Hospitalet deLlobregat, Madrid, Palma de Mallorca, Valencia
2023-09-22
Recruiting
AstraZeneca
Phase 3
231
Badalona, Barcelona, Esplugues de Llobregat (Barc), Madrid, Sabadell, Valencia, Villarreal
2023-08-24
Active, closed
AstraZeneca
Phase 2
188
Badalona, Barcelona, Bilbao, Granada, L'Hospitalet de Llobregat, Madrid, Seville, Valencia
2023-03-06
Active, closed
AstraZeneca
Phase 3
1,350
Las Palmas de Gran Canaria, Lugo, Madrid, Santander, Seville, Valencia, Zaragoza
2022-12-29
Active, closed
AstraZeneca
Phase 3
1,174
Barcelona, Bilbao (Vizcaya), Elche(Alicante), Madrid, Málaga, Palma de Mallorca, Toledo, Valencia
2022-11-28
By invitation
AstraZeneca
Phase 3
214
Barcelona, Girona, Madrid, Marbella, Santiago de Compostela, Valencia
2022-04-19
Active, closed
AstraZeneca
Phase 3
390
Barcelona, Málaga, Valencia, Vigo, Zaragoza
2022-02-21
Active, closed
AstraZeneca
Phase 3
1,051
Barcelona, Granada, Madrid, Santiago de Compostela, Valencia
2022-02-07
Active, closed
AstraZeneca
Phase 3
454
L'Hospitalet de Llobregat, Madrid, Málaga, Valencia
2021-10-28
Active, closed
AstraZeneca
Phase 3
367
Barcelona, Madrid, Santiago de Compostela, Seville, Valencia
2021-06-08
Recruiting
AstraZeneca
Phase 1
304
Badalona, Madrid, Seville, Valencia
2021-03-09
Active, closed
AstraZeneca
Phase 2
31
Seville, Valencia
2021-02-23
Active, closed
AstraZeneca
Phase 3
957
Barcelona, Madrid, Málaga, Ourense, Santander, Seville, Valencia
2020-11-17
Active, closed
AstraZeneca
Phase 3
370
Barcelona, Madrid, Valencia
2020-10-02
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Barcelona, Córdoba, Madrid, Valencia
2020-08-18
Active, closed
AstraZeneca
Phase 3
185
Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Granada, Madrid, Pamplona, Valencia
2020-08-04
Active, closed
AstraZeneca
Phase 3
866
A Coruña, Barcelona, Córdoba, El Palmar, Madrid, San Sebastián, Seville, Valencia
2020-07-24
Active, closed
AstraZeneca
Phase 3
923
Badalona, Barcelona, Hospitalet deLlobregat, Jaén, Madrid, Málaga, Seville, Valencia
2019-06-25
Active, closed
AstraZeneca
Phase 2
367
Córdoba, Donostia / San Sebastian, Madrid, Málaga, Valencia, Zaragoza
2019-01-09
Active, closed
AstraZeneca
Phase 1
396
Barcelona, Madrid, Seville, Valencia
2018-10-11
Active, closed
AstraZeneca
Phase 3
730
Barcelona, Madrid, Oviedo, Seville, Valencia, Zaragoza
2018-09-27
Active, closed
AstraZeneca
Phase 3
216
Barcelona, Madrid, Málaga, San Sebastián, Seville, Valencia
2018-07-19
Active, closed
AstraZeneca
Phase 2
273
Barcelona, Cáceres, Madrid, Palma de Mallorca, San Sebastián, Sant Cugat del Vallès, Seville, Valencia
2018-03-07
Active, closed
AstraZeneca
Phase 3
987
A Coruña, Badajoz, Badalona, Barcelona, Madrid, Santander, Valencia, Zaragoza
2017-03-27
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Barcelona, Córdoba, Girona, Madrid, Pamplona, Valencia
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Barcelona, Córdoba, Hospitalet deLlobregat(Barcelo, Madrid, Valencia
2013-08-26
Active, closed
AstraZeneca
Phase 2
162
Madrid, Valencia
2010-02-04
Rows per page Showing 1–60 of 60
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/valencia

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 60 of those studies with a site in Valencia that also match the filters currently applied.

How many clinical trials are recruiting in Valencia?

31 of the 60 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 28 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Valencia), 60 studies
PhaseStudiesRecruitingShare
Phase 3361660%
Phase 215725%
Phase 1/26610%
Phase 1325%

Most active sponsors

Lead sponsors with the most studies (Valencia)
Lead sponsorStudiesRecruiting
AstraZeneca6031
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.